(FM) Inmunología
Departamento académico
Luis Alfonso
Gurpide Ayarra
Consultor Médico
Publicaciones en las que colabora con Luis Alfonso Gurpide Ayarra (16)
2024
2021
-
Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma
Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337
2019
-
Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer
International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001
-
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Nature Medicine, Vol. 25, Núm. 3, pp. 470-476
2018
-
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319
-
Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer
Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483
2017
-
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97
2016
-
Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
OncoImmunology, Vol. 5, Núm. 1
2013
-
Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein
Cancer Research, Vol. 73, Núm. 1, pp. 139-149
2011
2010
-
Selection of extreme phenotypes: The role of clinical observation in translational research
Clinical and Translational Oncology, Vol. 12, Núm. 3, pp. 174-180
2009
-
Clinical development of combination strategies in immunotherapy: Are we ready for more than one investigational product in an early clinical trial?
Immunotherapy, Vol. 1, Núm. 5, pp. 845-853
-
Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array
British Journal of Cancer, Vol. 101, Núm. 11, pp. 1876-1883
-
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
British Journal of Cancer, Vol. 100, Núm. 7, pp. 1111-1119
2007
-
Nuevos tratamientos para el carcinoma renal
Anales del sistema sanitario de Navarra, Vol. 30, Núm. 3, pp. 393-403